BioPharma
Cidara Touts Positive Phase II Antifungal Data
Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year. Source: BioSpace
Read MoreNew Study Indicates DNA Plays Role in Gender Identity
In the world of politics and civil rights, the ideas of gender and transgender have been a hot-button issue. But a new study suggests that transgender people may have a genetic disposition that influences their identity. Source: BioSpace
Read More6 Biotech Companies with Upside Potential
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development. Source: BioSpace
Read MoreFDA Gives Go-Ahead for Tetra's Phase II Trial
Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders. Source: BioSpace
Read MoreWhat Astronaut Peggy Whitson Can Teach Us About Rejection in the Workplace
Peggy Whitson has spent 665 days in space, more than any other US astronaut and more than any other female astronaut in the world. You don’t associate Peggy Whitson with failure. But… Source: BioSpace
Read MoreJohnson & Johnson Selling LifeScan Unit for $2.1 Billion
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion. Source: BioSpace
Read MoreAMO Pharma Sees Positive Results in Phase II Trials
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks. Source: BioSpace
Read MoreAdaptimmune Sees Positive Early Results in Cancer Treatment
Adaptimmune reported it saw three partial responses in three of the four myxoid/ round cell liposarcoma (MRCLS) patients the company dosed with its NY-ESO SPEAR T-cells. Source: BioSpace
Read MoreArbor Biotechnologies Comes Out of Stealth Mode
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round. Source: BioSpace
Read MoreTheranos Serves as a Cautionary Tale for Biotech Funding
There are dangers in biotech funding and Theranos should serve as a warning. Source: BioSpace
Read More